The atherogenic index of plasma and the risk of mortality in incident dialysis patients: Results from a nationwide prospective cohort in Korea. by 媛뺤떊�슧 et al.
RESEARCH ARTICLE
The atherogenic index of plasma and the risk
of mortality in incident dialysis patients:
Results from a nationwide prospective cohort
in Korea
Mi Jung Lee1, Jung Tak Park2, Seung Hyeok Han2, Yong-Lim Kim3,4, Yon Su Kim5,4, Chul
Woo Yang6,4, Nam-Ho Kim7,4, Shin-Wook Kang2,4, Hyung Jong Kim1*, Tae-Hyun Yoo2*
1 Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea,
2 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, 3 Department of
Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, 4 Clinical Research
Center for End-Stage Renal Disease, Daegu, Korea, 5 Department of Internal Medicine, Seoul National
University College of Medicine, Seoul, Korea, 6 Department of Internal Medicine, Catholic University of Korea
College of Medicine, Seoul, Korea, 7 Department of Internal Medicine, Chonnam National University Medical
School, Gwangju, Korea
* khj04@cha.ac.kr (HJK); yoosy0316@yush.ac (THY)
Abstract
Background
The atherogenic index of plasma (AIP), which is the logarithmic ratio of triglyceride (TG) to
high-density lipoprotein cholesterol (HDL-C), had a linear relationship with clinical outcomes
in the general population. However, the association of each lipid profile, TG and HDL-C,
with survival was not straightforward in dialysis patients. This non-linear association led us
to further investigate the prognostic impact of the AIP in these patients.
Methods
From a nationwide prospective cohort, 1,174 incident dialysis patients were included.
Patients were categorized into quintiles according to the AIP. An independent association of
the AIP with all-cause and cardiovascular mortality was determined.
Results
During a mean follow-up duration of 33.2 months, 170 patients (14.5%) died, and cardiovas-
cular death was observed in 55 patients (4.7%). Multivariate Cox analyses revealed that the
lowest (quintile 1, hazard ratio [HR] = 1.76, 95% confidence interval [CI] = 1.02–3.03) and
the highest (quintile 5, HR = 2.15, 95% CI = 1.26–3.65) AIP groups were significantly associ-
ated with higher all-cause mortality compared to patients in quintile 3 (reference group). In
terms of cardiovascular mortality, only the highest AIP group (quintile 5, HR = 2.59, 95% CI
= 1.06–6.34) was significantly associated with increased risk of mortality. Sensitivity analy-
ses showed that a U-shaped association between the AIP and all-cause mortality remained
significant in non-diabetic and underweight to normal body mass index patients.
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Conclusions
Both the highest and the lowest AIP groups were independently associated with all-cause
mortality, showing a U-shaped association. It suggested further studies are needed to iden-
tify targets and subgroups that can benefit from intervention of the AIP in incident dialysis
patients.
Introduction
Dyslipidemia is an established risk factor for cardiovascular disease in the general population
[1]. In particular, atherogenic dyslipidemia, which means a concurrence of high triglyceride
(TG) and low high-density lipoprotein cholesterol (HDL-C) levels, has been shown to be
closely associated with adverse clinical outcomes in the general population [2], as well as high
risk patients [3–6]. Gaziano et al. [2] first explored the combining effect of elevated TG and
low HDL-C and demonstrated that the TG to HDL-C ratio was a strong predictor of myocar-
dial infarction in the general population. Moreover, a greater TG/HDL-C ratio was implicated
with fatal or non-fatal cardiovascular disease [3–6] and all-cause mortality [3, 6] in women
with high cardiovascular risk [3], obese type 2 diabetes patients [4], patients with prior stroke
or transient ischemic attack receiving statin therapy [5], and essential hypertension patients
[6]. The atherogenic index of plasma (AIP), which is the logarithmic ratio of TG to HDL-C,
was also found to be correlated with cardiovascular risk [7]. The close association of the AIP
and cardiovascular risk has been mainly explained by lipoprotein particle size [7], insulin resis-
tance [8–10], and metabolic syndrome [11], all of which are important risk factors for cardio-
vascular disease. To date, two studies have investigated the association between the TG/
HDL-C ratio and clinical outcomes in end-stage renal disease (ESRD) patients treated by dial-
ysis therapy [12, 13]. These studies indicated that the highest quintile or quartile of the TG/
HDL-C ratio was associated with increased risk of cardiovascular and all-cause mortality com-
pared with the lowest part [12, 13]. However, several previous studies showed that the prog-
nostic impact of each lipid profile, TG and HDL-C, was not straightforward in dialysis patients
[14–17]. In hemodialysis (HD) patients, the association between TG and mortality showed a
U-shaped association [15], whereas a direct association of TG with mortality was observed in
peritoneal dialysis (PD) patients [14]. In terms of HDL-C, there have been discordant results
from no association [15, 17] to U-shaped relationship [16]. Furthermore, the retrospective
nature of previous studies [13] and limited data of a single center study [12, 13] led us to further
investigate the prognostic impact of the AIP in our cohort. Therefore, in the present study, the
association of the AIP with all-cause and cardiovascular mortality was evaluated in an incident
dialysis population from a nationwide prospective observational multicenter cohort.
Materials and methods
Study participants
All ESRD patients who started HD or PD between August 1, 2008 and December 31, 2014 at
31 centers of the Clinical Research Center for ESRD (CRC for ESRD) in the Republic of Korea
were initially screened for this study. This study is part of a nationwide multicenter prospective
cohort study of ESRD patients that aimed to improve clinical outcomes and to develop effi-
cient treatment guidelines in the Republic of Korea (clinicaltrial.gov NCT00931970). Patients
who refused to participate in the study, who did not maintain dialysis for the first 3 months,
who had missing with TG or HDL-C, or who did not have intact parathyroid hormone, high-
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sensitivity C-reactive protein (hs-CRP), residual kidney function or residual urine output data
were excluded from the initially screened 2,189 patients. In total, 1,174 incident dialysis pa-
tients were included in the final analyses (Fig 1). Meanwhile, there were no significant differ-
ences in baseline characteristics, all-cause mortality, and cardiovascular mortality between
1,174 included and 533 excluded patients, except for the cause of chronic kidney disease (S1
Table). Patients who were excluded had more kidney failure with unknown causes. This study
was carried out in accordance with the Declaration of Helsinki. The study protocol was ap-
proved by the Institutional Review Board of each participating center (S1 Text for full names),
and all patients provided their written informed consent to participate in the study.
Data collection
Demographic, clinical, and laboratory data were extracted from the CRC for ESRD electronic
database. Demographic and clinical data including age, sex, dialysis modality, primary renal dis-
ease, comorbidities, body mass index (BMI), and medications were collected at the study enroll-
ment. Laboratory data were measured from fasting blood samples at 3 months after dialysis
initiation. AIP was calculated from plasma TG and HDL-C (log [TG/HDL-C]). In HD patients,
blood was taken at the predialysis period and a single pooled Kt/V urea was obtained on the day
of the midweek dialysis session. In PD patients, blood was taken under usual overnight peritoneal
dialysate volume and glucose concentrations, and weekly peritoneal Kt/V urea was calculated
using PD Adequest1, version 2.0 for Windows software (Baxter Healthcare, Deerfield, IL, USA).
Residual kidney function and residual urine volume were determined by timed urine collection,
in a 44-hour interdialytic period in HD patients and 24-hour urine collection in PD patients.
Follow-up and outcomes
Study participants were followed until September 30, 2015. All death events and the cause of
death were retrieved from the CRC for ESRD database and collated with the medical records
at each participating center. Death events were also confirmed by the Korea National Statistics
database. Cardiovascular death was defined as death from myocardial infarction, unstable
Fig 1. Flow diagram of patients. Among 2,189 incident dialysis patients, 1,015 patients were excluded. A
total of 1,174 patients were finally analyzed. Abbreviations: CRC, clinical research center; ESRD, end-stage
renal disease; HD, hemodialysis; HDL-C, high-density lipoprotein cholesterol; PD, peritoneal dialysis; TG,
triglyceride.
https://doi.org/10.1371/journal.pone.0177499.g001
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angina, new onset, or worsening of congestive heart failure, stroke, or arterial revasculariza-
tion. Loss to follow-up, kidney transplantation, or recovery of renal function was censored at
the end of dialysis treatment.
Statistical analysis
Statistical analyses were performed using SPSS for Windows version 20.0 (IBM Corp.,
Armonk, NY, USA) and R (R Foundation for Statistical Computing, Vienna, Austria; www.r-
project.org). Continuous variables were expressed as the mean ± standard deviation or the
median (interquartile range [IQR]) and categorical variables were expressed as a number (per-
centage). Patients were categorized into five groups according to the AIP quintiles (Q1 to Q5).
Baseline characteristics were compared among the groups using ANOVA with the Bonferroni
post-hoc test or the Kruskal-Wallis test for continuous variables, and the chi-square test for
categorical variables. The association between the AIP and baseline characteristics was exam-
ined by uni- and multivariate linear regression analyses. The prognostic value of the AIP was
ascertained by Cox proportional hazard regression analyses. Multivariate Cox models were
constructed including age, sex, presence of diabetes mellitus, prior history of cardiovascular
disease, dialysis modality, BMI, serum albumin levels, hs-CRP levels, and residual urine vol-
ume, which were significant risk factors for mortality in the univariate Cox analyses or inde-
pendent variables associated with the AIP in the linear regression analyses. Sensitivity analyses
were done only for all-cause mortality due to the limited number of cardiovascular death
events. Because there was interaction between the AIP and BMI for all-cause mortality (P for
interaction = 0.03), subgroup analyses were performed. Patients were divided into under-
weight to normal BMI (BMI <22.9 kg/m2) and overweight to obese (BMI23.0 kg/m2)
groups using the World Health Organization recommendations for Asian populations [18].
Although there was no interaction between the AIP and diabetes mellitus (P for interac-
tion = 0.12) or dialysis modality (P for interaction = 0.62), stratified analyses were performed
due to clinical relevance. P<0.05 was considered statistically significant.
Results
Baseline characteristics according to the AIP categories
Baseline demographics, clinical characteristics, and laboratory data according to the AIP cate-
gories are shown in Table 1 and Table 2. The mean age was 55.4±14.2 years, and 721 patients
(61.4%) were men. In total, 740 HD and 434 PD patients were included in this study. The
median value of the AIP was 0.47 (IQR, 0.26–0.66) for all patients, and the median value of the
AIP for each quintile was 0.06, 0.31, 0.47, 0.62, and 0.84, respectively. In the patients, there was
a significant increase of diabetes, BMI, serum glucose, total cholesterol, and low-density lipo-
protein cholesterol (LDL-C) concentrations as the AIP increased.
Association between AIP and baseline characteristics
In univariate linear regression analyses, the BMI and log hs-CRP levels were positively associ-
ated with the AIP. The AIP was significantly higher in PD patients and diabetic patients. Mul-
tivariate linear regression analyses indicated that a higher AIP was independently associated
with PD, diabetes mellitus, a higher BMI, and log hs-CRP concentrations (Table 3).
Independent prognostic value of AIP for mortality
During a mean follow-up duration of 33.2±18.2 months, 170 patients (14.5%) died, and car-
diovascular death was observed in 55 patients (4.7%) (Table 4). Incidence rates of all-cause
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death and cardiovascular death were the lowest (21 patients, 8.9%; 7 patients, 3.0%, respec-
tively) in patients in the AIP quintile 3 and the highest (40 patients, 17.1%; 16 patients, 6.8%,
respectively) in patients in the AIP quintile 5 group.
To determine the independent prognostic value of the AIP for all-cause and cardiovascular
mortality, Cox’s regression analyses were performed (Fig 2). Multivariate Cox analyses demon-
strated that the lowest (Q1) and the highest (Q5) AIP groups were independently associated
with higher all-cause mortality compared with patients of quintile 3 (reference group). The
hazard ratios (HRs) of each AIP group for all-cause mortality were 1.76 (Q1, 95% confidence
interval [95% CI] = 1.02–3.03), 1.67 (Q2, 95% CI = 0.97–2.86), 1.68 (Q4, 95% CI = 0.98–2.89),
and 2.15 (Q5, 95% CI = 1.26–3.65), respectively. In terms of cardiovascular mortality, only the
Table 1. Baseline demographics and clinical characteristics of subjects according to the AIP categories.
All Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
(min, max) (-0.57, 0.20) (0.21, 0.39) (0.40, 0.54) (0.55, 0.70) (0.71, 1.58)
(n = 1,174) (n = 234) (n = 236) (n = 235) (n = 235) (n = 234) P
AIP 0.47 (0.26–0.66) 0.06 (-0.58–0.14) 0.31 (0.26–0.36) 0.47 (0.42–0.51) 0.62 (0.58–0.66) 0.84 (0.77–0.95) <0.001
Age, years 55.4 ± 14.2 55.1 ± 15.0 57.0 ± 14.0 54.5 ± 14.6 55.8 ± 13.3 54.4 ± 14.0 0.24
Men, n (%) 721 (61.4%) 151 (64.5%) 142 (60.2%) 133 (56.6%) 144 (61.3%) 151 (64.5%) 0.36
Hemodialysis, n (%) 740 (63.0%) 158 (67.5%) 153 (64.8%) 147 (62.6%) 140 (58.6%) 142 (60.7%) 0.39
Primary renal disease, n (%) 0.33
Diabetic nephropathy 599 (51.0%) 108 (46.2%) 109 (46.2%) 117 (49.8%) 128 (54.5%) 137 (58.5%)
Hypertensive nephrosclerosis 209 (17.8%) 47 (20.1%) 49 (20.8%) 43 (18.3%) 35 (14.9%) 35 (15.0%)
Glomerulonephritis 168 (14.3%) 38 (16.2%) 30 (12.7%) 39 (16.6%) 34 (14.5%) 27 (11.5%)
Polycystic kidney disease 23 (2.0%) 7 (3.0%) 6 (2.5%) 5 (2.1%) 3 (1.3%) 2 (0.9%)
aOthers 38 (3.2%) 4 (1.7%) 10 (4.2%) 9 (3.8%) 6 (2.6%) 9 (3.8%)
Unknown 137 (11.7%) 30 (12.8%) 32 (13.6%) 22 (9.4%) 29 (12.3%) 24 (10.3%)
Comorbid disease, n (%)
Diabetes mellitus 661 (55.3%) 116 (49.6%) 127 (53.8%) 127 (54.0%) 141 (60.0%) 150 (64.1%) 0.01
CAD 160 (13.6%) 29 (12.4%) 26 (11.0%) 34 (14.5%) 37 (15.7%) 34 (14.5%) 0.58
PAD 97 (8.3%) 23 (9.8%) 16 (6.8%) 19 (8.1%) 19 (8.1%) 20 (8.5%) 0.83
CVA 94 (8.0%) 18 (7.7%) 21 (8.9%) 16 (6.8%) 21 (8.9%) 18 (7.7%) 0.9
CHF 160 (13.6%) 25 (10.7%) 34 (14.4%) 33 (14.0%) 35 (14.9%) 33 (14.1%) 0.69
bCVD 373 (31.8%) 74 (31.6%) 68 (28.8%) 77 (32.8%) 81 (34.5%) 73 (31.2%) 0.76
Smoker, n (%) 544 (46.3%) 104 (44.4%) 113 (47.9%) 97 (41.3%) 107 (45.5%) 123 (52.6%) 0.15
SBP, mmHg 141.8 ± 22.5 142.9 ± 23.0 143.3 ± 22.9 141.1 ± 22.2 140.3 ± 21.3 141.2 ± 22.8 0.54
DBP, mmHg 78.2 ± 13.7 78.7 ± 14.6 78.1 ± 13.8 77.8 ± 12.9 77.8 ± 13.7 78.6 ± 13.7 0.9
BMI, kg/m2 22.9 ± 3.3 21.6 ± 2.9 22.4 ± 3.0 22.9 ± 3.0 23.4 ± 3.6 24.1 ± 3.5 <0.001
Medications, n (%)
RAS blockers 712 (60.6%) 143 (61.1%) 149 (63.1%) 145 (61.7%) 137 (58.3%) 138 (59.0%) 0.82
Beta-blockers 615 (52.4%) 117 (50.0%) 124 (52.5%) 115 (48.9%) 133 (56.6%) 126 (53.8%) 0.47
Calcium channel blockers 746 (63.5%) 146 (62.4%) 158 (66.9%) 154 (65.5%) 135 (57.4%) 153 (65.4%) 0.21
Diuretics 681 (58.0%) 136 (58.1%) 140 (59.3%) 128 (54.5%) 141 (60.0%) 136 (50.4%) 0.78
Note: Data are expressed as the mean ± standard deviation, median (interquartile range), or number of patients (percent).
aOthers: Interstitial nephritis, obstructive uropathy, and post status of nephrectomy
bCVD: A composite of CAD, PAD, CVA, and CHF
Abbreviations: AIP, atherogenic index of plasma; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CVD, cardiovascular
disease; CVA, cerebrovascular accidents; DBP, diastolic blood pressure; PAD, peripheral artery disease; RAS, renin-angiotensin system; SBP, systolic
blood pressure.
https://doi.org/10.1371/journal.pone.0177499.t001
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highest AIP group (Q5, HR = 2.59, 95% CI = 1.06–6.34) was significantly associated with
increased risk of cardiovascular mortality. The other groups did not show a significant rela-
tionship with cardiovascular mortality (Q1, HR = 1.63, 95% CI = 0.63–4.26; Q2, HR = 1.15,
95% CI = 0.43–3.12; Q4, HR = 1.75, 95% CI = 0.69–4.47; Q3 as reference group). Furthermore,
additional adjustment of serum calcium and phosphorus did not change the main results. The
Table 2. Laboratory data at 3 months after dialysis initiation according to the AIP categories.
All Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
(min, max) (-0.57, 0.20) (0.21, 0.39) (0.40, 0.54) (0.55, 0.70) (0.71, 1.58)
(n = 1,174) (n = 234) (n = 236) (n = 235) (n = 235) (n = 234) P
AIP 0.47 (0.26–0.66) 0.06 (-0.58–0.14) 0.31 (0.26–0.36) 0.47 (0.42–0.51) 0.62 (0.58–0.66) 0.84 (0.77–0.95) <0.001
Hemoglobin, g/L 88 ± 16 88 ± 16 88 ± 17 88 ± 18 88 ± 16 89 ± 16 0.85
BUN, mmol/L 29.8 ± 13.4 30.6 ± 13.1 29.3 ± 14.0 30.1 ± 13.5 29.3 ± 12.1 29.6 ± 14.1 0.80
Creatinine, μmol/L 769 ± 362 769 ± 362 743 ± 309 796 ± 371 778 ± 371 778 ± 380 0.49
Albumin, g/L 33 ± 6 33 ± 6 33 ± 6 34 ± 6 33 ± 6 36 ± 6 0.62
Glucose, mmol/L 7.7 ± 4.1 7.3 ± 3.6 7.3 ± 3.8 7.4 ± 3.8 8.3 ± 4.6 8.2 ± 4.5 0.01
TG, mmol/L 3.3 ± 2.1 1.5 ± 0.5 2.3 ± 0.6 3.0 ± 0.8 3.7 ± 0.9 5.9 ± 2.8 <0.001
Total cholesterol, mmol/L 4.1 ± 1.3 3.8 ± 1.0 4.0 ± 1.1 4.0 ± 1.1 4.2 ± 1.3 4.6 ± 1.7 <0.001
LDL-C, mmol/L 2.3 ± 1.0 2.0 ± 0.7 2.3 ± 0.9 2.3 ± 0.9 2.5 ± 1.0 2.5 ± 1.3 <0.001
HDL-C, mmol/L 1.0 ± 0.4 1.4 ± 0.4 1.2 ± 0.3 1.0 ± 0.3 0.9 ± 0.2 0.7 ± 0.2 <0.001
Calcium, mmol/L 2.0 ± 0.3 1.9 ± 0.3 1.9 ± 0.3 1.9 ± 0.3 2.0 ± 0.3 2.0 ± 0.3 0.79
Phosphorus, mmol/L 1.8 ± 0.6 1.8 ± 0.7 1.8 ± 0.6 1.8 ± 0.6 1.8 ± 0.7 1.8 ± 0.6 0.77
iPTH, ng/L 215 (123–353) 227 (124–367) 205 (122–354) 210 (124–320) 196 (127–320) 200 (117–325) 0.43
hs-CRP, mg/L 2.6 (0.7–10.3) 2.6 (0.6–9.4) 2.6 (0.6–12.7) 2.5 (0.6–9.5) 2.9 (0.8–9.2) 3.1 (0.9–12.5) 0.20
aDialysis Kt/V urea (HD) 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.3 1.4 ± 0.3 1.4 ± 0.4 1.4 ± 0.5 0.42
bWeekly Kt/V urea (PD) 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.6 0.75
RKF, mL/min/1.73m2 5.5 ± 3.7 5.7 ± 4.7 5.6 ± 3.3 5.1 ± 3.1 5.4 ± 2.9 5.5 ± 4.3 0.49
Urine volume, L/day 1.1 ± 0.7 1.0 ± 0.6 1.1 ± 0.7 1.0 ± 0.6 1.0 ± 0.6 1.2 ± 0.8 0.11
Note: Data are expressed as mean ± standard deviation or median (interquartile range).
aDialysis Kt/V urea were meausred in 740 HD patients.
bWeekly peritoneal Kt/V urea were measured in 434 PD patients.
Abbreviations: AIP, atherogenic index of plasma; BUN, blood urea nitrogen; HD, hemodialysis; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-
sensitivity C-reactive protein; iPTH, intact parathyroid hormone; LDL-C, low density lipoprotein cholesterol; PD, peritoneal dialysis; RKF, residual kidney
function; TG, triglyceride.
https://doi.org/10.1371/journal.pone.0177499.t002
Table 3. Uni- and multivariate linear regression analysis of clinical and biochemical variables for higher AIP.
Univariate aMultivariate
β (95% CI) P β (95% CI) P
Age (per year) 0.001 (-0.002, 0.001) 0.47 -0.001 (-0.002, 0.001) 0.14
Women (vs. men) 0.001 (-0.036, 0.036) 0.9 0.015 (-0.020, 0.050) 0.40
PD (vs. HD) 0.046 (0.010, 0.082) 0.01 0.057 (0.022, 0.093) 0.002
DM (vs. no) 0.053 (0.017, 0.088) 0.003 0.044 (0.008, 0.0794) 0.02
BMI (per kg/m2) 0.024 (0.019, 0.029) <0.001 0.024 (0.018, 0.029) <0.001
log hs-CRP (per mg/L) 0.022 (0.001, 0.043) 0.04 0.026 (0.004, 0.047) 0.02
aAdjusted for age, sex, dialysis modality, DM, BMI, and log hs-CRP levels
Abbreviations: AIP, atherogenic index of plasma; BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; HD, hemodialysis; hs-CRP, high-
sensitivity C-reactive protein; PD, peritoneal dialysis.
https://doi.org/10.1371/journal.pone.0177499.t003
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lowest (Q1, HR = 1.79, 95% CI = 1.03–3.11) and the highest (Q5, HR = 2.00, 95% CI = 1.17–
3.43) AIP groups were significantly associated with greater risk of all-cause mortality com-
pared with the reference group (Q3). The highest AIP group (Q5, HR = 2.55, 95% CI = 1.03–
6.30) showed a higher risk of cardiovascular mortality (S2 Table).
For sensitivity analyses, the independent prognostic value of the AIP for all-cause mortality
was tested in several subgroups (Fig 3). The prognostic value of the highest quintile of the AIP
(Q5) for all-cause mortality was significant in both diabetic (HR = 2.90, 95% CI = 1.01–8.32)
and non-diabetic (HR = 2.01, 95% CI = 1.07–3.75) patients. However, an increased mortality
risk of the lowest AIP groups was significant only in non-diabetic patients (HR = 2.29, 95%
CI = 1.21–4.32). Similarly, the highest AIP group was independently associated with increased
risk of all-cause mortality in both the underweight to normal BMI (HR = 2.08, 95% CI = 1.01–
4.30) and overweight to obese (HR = 2.97, 95% CI = 1.31–6.76) groups. However, a U-shaped
association was significant in only the underweight to normal BMI patients (AIP Q1, HR =
2.07, 95% CI = 1.04–4.11). With regard to dialysis modality, a U-shaped association remained
significant in both HD and PD patients. The lowest (Q1, HR = 1.97, 95% CI = 1.05–3.70 in
HD and HR = 1.88, 95% CI = 1.01–3.50 in PD) and the highest (Q5, HR = 2.47, 95% CI =
1.34–4.56 in HD and HR = 2.35, 95% CI = 1.28–4.30 in PD) AIP groups were significantly
associated with greater all-cause mortality compared with patients in quintile 3.
Discussion
In the present study, we investigated the prognostic value of the AIP on all-cause and cardio-
vascular mortality in incident dialysis patients from a nationwide prospective cohort of ESRD
patients. Both the lowest (0.20) and the highest (0.71) AIP groups were independently
associated with all-cause mortality risk, showing a U-shaped association. In terms of cardiovas-
cular mortality, only the highest AIP group (0.71) showed a significant risk factor. A U-
shaped association between the AIP and all-cause mortality was significant in non-diabetic
and underweight to normal BMI patients. These findings suggested that the prognostic impact
of the AIP was not straightforward.
The AIP has been shown to be a good marker of atherogenicity [7, 19] and implicated with
adverse clinical outcomes in the general population [2] and various populations with high car-
diovascular risk [3–6, 12, 13]. The prognostic impact of concurrence of elevated TG and low
HDL-C was first investigated in the general population [2]. Patients in the highest quintile of
the TG/HDL-C ratio had a 16-fold increased risk of myocardial infarction compared with the
lowest quintile [2]. Furthermore, a higher TG/HDL-C ratio was also a strong independent pre-
dictor of all-cause and cardiovascular mortality in female patients referred for clinically indi-
cated coronary angiography [3]. In patients with prior history of stroke or transient ischemic
attacks receiving statin therapy, major cardiovascular events were higher in subjects with ath-
erogenic dyslipidemia, defined as high TG ( 150 mg/dL) and low HDL-C ( 40 mg/dL), sug-
gesting a significant relationship of atherogenic dyslipidemia with residual cardiovascular risk
Table 4. All-cause and cardiovascular death events according to the AIP categories.
All Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
(n = 1,174) (n = 234) (n = 236) (n = 235) (n = 235) (n = 234)
Follow-up duration (month) 33.2 ± 18.2 34.5 ± 17.4 32.8 ± 17.9 31.6 ± 18.9 35.3 ± 18.2 31.9 ± 18.6
All-cause death, n (%) 170 (14.5%) 36 (15.4%) 37 (15.7%) 21 (8.9%) 36 (15.3%) 40 (17.1%)
Cardiovascular death, n (%) 55 (4.7%) 11 (4.7%) 9 (3.8%) 7 (3.0%) 12 (5.1%) 16 (6.8%)
Abbreviations: AIP, atherogenic index of plasma.
https://doi.org/10.1371/journal.pone.0177499.t004
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Fig 2. Hazard ratios of all-cause and cardiovascular mortality for AIP categories in 1,174 incident dialysis patients. (A) all-cause
mortality and (B) cardiovascular mortality. Model 1: adjusted for sex, age, diabetes mellitus, previous history of cardiovascular disease,
dialysis modality, and body mass index; Model 2: Model 1+serum albumin, log hs-CRP, and residual urine volume. Abbreviations: AIP,
atherogenic index of plasma; hs-CRP, high-sensitivity C-reactive protein.
https://doi.org/10.1371/journal.pone.0177499.g002
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Fig 3. Adjusted hazard ratios of all-cause mortality for AIP categories in different subgroups. (A) in 513 non-diabetic,
(B) in 661 diabetic patients, (C) in 653 underweight to normal BMI patients, (D) in 521 overweight to obese patients, (E) in
740 HD, and (F) in 434 PD patients. Adjusted for age, sex, dialysis modality, modified Charlson comorbidity index, BMI,
serum albumin, log hs-CRP, and residual urine volume. In subgroup analyses regarding HD and PD, dialysis modality was
not adjusted. Abbreviations: AIP, atherogenic index of plasma; BMI, body mass index; hs-CRP, high-sensitivity C-reactive
protein.
https://doi.org/10.1371/journal.pone.0177499.g003
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[5]. To date, in ESRD patients, there have been two single-center studies evaluating the prog-
nostic impact of the TG/HDL-C ratio [12, 13]. Wu et al. [13] investigated the effect of the TG/
HDL-C ratio on all-cause and cardiovascular mortality in a retrospective cohort of 1,170 PD
patients. In their study, the highest quintile of the TG/HDL-C ratio (4.19) showed a signifi-
cant risk factor for cardiovascular and all-cause mortality. Another study also showed that
patients with higher TG/HDL-C ratios (>6.6) had a higher incidence of cardiovascular events,
cardiovascular death, and all-cause death in 602 dialysis patients [12]. In the present study, we
demonstrated that the highest quintile of the AIP (0.71), which is 5.12 for TG/HDL-C ratio,
was significantly associated with a 2.15-fold increase in all-cause mortality and 2.59-fold
increase in cardiovascular mortality, even after the adjustment of confounding variables.
Although the exact mechanism by which a higher AIP affects increased risk of all-cause and
cardiovascular mortality remains unclear, the association of AIP with LDL-C particle size [7],
insulin resistance [8–10], and metabolic syndrome [11] can be possible explanations. In a
study of 1,433 subjects from 35 cohorts with various risks of atherosclerosis such as hyperten-
sion, type 2 diabetes, and dylipidemia, and patients with positive or negative angiography find-
ings, there was a strong positive correlation between AIP and cholesterol esterification rates
in apoB-lipoprotein-depleted plasma, an indirect measure of LDL-C particle size [7]. This
finding suggested that the AIP directly correlated with the risk of atherosclerosis and that the
AIP could be used as a marker of plasma atherogenecity. Another possible explantation for
increased cardiovascular risk of a higher AIP could be the association with insulin resistance
and metabolic syndrome. The ratio of plasma TG/HDL-C was the best predictor of insulin
resistance, which was determined by the steady-state plasma glucose concentration during the
insulin suppression test [8]. Insulin resistance increased the concentrations of TG and HDL-C,
and in turn, the AIP might affect insulin secretion, β-cell dysfunction, and cause poor glycemic
control in type 2 diabetes patients [9, 10]. Moreover, a high AIP was associated with obesity
and predicted the incidence of type 2 diabetes, hypertension, and metabolic syndrome [11].
Unfortunately, LDL-C particle size and insulin resistance were not measured in our study,
making it difficult to clarify the underlying mechanism for increased cardiovascular risk of a
high AIP in ESRD patients on dialysis. However, a cross-sectional evaluation of the AIP and
surrogates of cardiovascular disease in dialysis patients supported our findings [19, 20]. In a
study of 31 HD patients and 31 healthy volunteers, the AIP and carotid intima medial thick-
ness were higher in HD patients compared with controls [19]. There was a significant positive
correlation between the AIP and carotid intima medial thickness in HD patients. Another
study also showed that the AIP was significantly associated with increased epicardial adipose
tissue, the true visceral fat deposit of the heart in ESRD patients [20]. We did not perform
carotid artery ultrasonography or cardiac computed tomography in the current study, but a
further study with these cardiovascular surrogates may be helpful to verify a significant associ-
ation between the AIP and cardiovascular disease in ESRD patients.
Another main finding of this study was a U-shaped association between the AIP and all-
cause mortality in incident dialysis patients. Patients in the quintile 3 group of the AIP showed
the lowest incidence rate of death events, and the lowest and the highest quintiles of the AIP
were significantly associated with higher all-cause mortality risk, compared with patients in
the quintile 3 group. Although the reason for higher all-cause mortality risk in the lowest
AIP group was not clear, it can be speculated from the deleterious effects of low TG and high
HDL-C in dialysis patients. In a large cohort of HD patients, the best survival was observed
with moderately high levels (200–249 mg/dL) of TG, suggesting a higher mortality risk with
lower levels of TG [15]. This paradoxical higher mortality risk in the low TG group was ex-
plained by the effect of malnutrition and inflammation, which are important risk factors for
mortality in ESRD patients. In our study, the HRs of the quintile 1 and quintile 2 groups were
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attenuated after adjustment of serum albumin and hs-CRP concentrations, suggesting a possi-
ble association of low TG with malnutrition and inflammation and with mortality. Moreover,
emerging evidence indicating that HDL-C may not only be dysfunctional but may also have a
harmful effect by promoting inflammation in ESRD patients could be another explanation
[16, 21–25]. In a study of 12 stable HD patients and age-matched controls, monocyte anti-che-
motactic activity was significantly lower in ESRD patients than in controls, suggesting that
HDL-C has a deficient anti-inflammatory property in ESRD patients [21. Yamamoto et al. [24]
demonstrated that HDL-C from ESRD patients had reduced anti-chemotactic activity. Fur-
thermore, in vitro activated macrophages exposed to HDL-C of ESRD patients showed an
increased cytokine response (tumor necrosis factor-α, interleukin-6, and interleukin-1β) [24].
To investigate this pro-inflammatory property of HDL-C in ESRD patients, Weichhart et al.
[23] performed shotgun proteomics analyses and identified 49 HDL-associated proteins in a
uremia-specific pattern from HDL-C of HD patients. Of note, serum amyloid A mimicked
HDL-C of ESRD patients by promoting inflammatory cytokines, suggesting the role of specific
changes in molecular composition on pro-inflammatory property of HDL-C in ESRD patients
[23]. Moreover, the combination of high oxidized HDL-C and plasma interleukin-6 was signif-
icantly associated with increased carotid intima medial thickness and cardiovascular mortality
in prevalent HD patients [22]. Based on these results, we proposed that the deleterious effect of
HDL-C could explain the higher risk of mortality in the lowest AIP group. Unfortunately,
measurements of chemotactic activity, pro-inflammatory cytokine release from macrophage,
or oxidized isoform of HDL-C were not available in our study, so we were unable to confirm
our proposal.
Our sensitivity analyses demonstrated that higher all-cause mortality risk in the lowest
quintile of the AIP remained significant in non-diabetic patients and underweight to normal
BMI patients. Underweight patients had higher risk of mortality compared with overweight-
to-obese patients due to the adverse effects of nontraditional risk factors such as malnutrition
and inflammation. Therefore, we surmised that the combined risk of low AIP and under-
weight-to-normal BMI via malnutrition and inflammation might lead to an amplification of
the mortality risk for the lowest AIP groups of patients. By contrast, the protective effect of
high BMI in overweight-to-obese patients might mitigate the harmful effect of the lowest AIP
group, resulting in no significant association with increased mortality risk in these popula-
tions. In terms of diabetes, the higher proportion of underweight-to-normal BMI patients in
the non-diabetic group could be a possible explanation for the increased mortality risk of the
lowest AIP group. In fact, the proportion of underweight-to-normal BMI was significantly
higher in non-diabetic patients than in diabetic patients (318 patients [62.0%] vs. 335 patients
[50.7%], P<0.001). In addition, a study by Postorino et al. [26] demonstrated that abdominal
obesity showed a modifying effect on the association between TG and mortality in HD pa-
tients. In patients without abdominal obesity, a fixed (50 mg/dL) excess of TG was associated
with a progressively lower risk of mortality, but was associated with a higher risk of mortality
in patients with abdominal obesity. Although we did not examine abdominal obesity in this
study, we hypothesize that a modifying effect of obesity could be another possible explanation
for sensitivity analysis.
This study has several limitations. First, the AIP was not serially determined and we used
only baseline values of AIP. We suggest that the prognostic effects of changes in the AIP would
be worth investigating. Second, this study was not intended to evaluate the effect of lipid-low-
ering medications on mortality, and the data concerning lipid-lowering therapy were not avail-
able. Although the potential confounding effects of lipid-lowering medications on mortality
cannot be excluded, considering the results of recent clinical trials regarding lipid-lowering
therapy [27–29], we suggest that these data may not significantly alter the main findings of our
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study. Third, although there was no significant difference in the baseline characteristics, all-
cause mortality, and cardiovascular mortality between included and excluded patients, 1,174
patients may not be representative of the initially enrolled population, resulting in potential
selection bias. In this study, 261 patients who had missing with TG or HDL-C were excluded
from the final analysis. This study was conducted as an exploratory study to identify risk fac-
tors for adverse clinical outcomes; therefore, AIP was not a pre-specified variable. Patients
who did not have intact parathyroid hormone, hs-CRP, residual kidney function, or residual
urine output data were also excluded. Although many previous studies using nationwide data
did not include information regarding hs-CRP or residual kidney function, we excluded
patients who lacked measurements of these variables due to their significant effects on clinical
outcomes of dialysis patients. These factors can explain the reasons for the large number of
missing laboratory values. Meanwhile, the mean age of patients was relatively young and pro-
portion of patients treated with PD was high in the present study. According to a report of the
Korean Society of Nephrology [30], the mean age of all dialysis patients, including prevalent
and incident patients, was 56.7 years in 2008. The mean age steadily increased to 60.3 years in
2014. In 2014, the mean age of HD patients was 61.1 years, whereas the mean age of PD
patients was 55.4 years. Even though we did not select or focus on a young age group, we sur-
mise that the study period (from 2008 to 2012), participants (only incident dialysis patients),
and high proportion of PD contributed to the relatively young age of the study subjects. In our
study, patients were more likely to be treated with PD as an initial dialysis modality. Because
the majority of study participating centers were university hospitals, we postulate that struc-
tured pre-dialysis education program, experienced nephrologists familiar with PD, and ade-
quate medical resources for PD may contribute to higher selection for PD. In addition, HD
patients were more likely to be transferred to private dialysis units; therefore, the proportion of
excluded patients due to follow-up loss within the first 90 days was lower in PD patients than
in HD patients (among 224 patients, 204 patients [91.1%] in HD vs. 20 patients [8.9%] in PD,
P<0.001). Although subgroup analysis according to dialysis modality did not change the main
results, the high proportion of PD patients could lead to potential selection bias. Fourth, by the
virtue of the observational study design, this study did not include any information regarding
intervention to reduce mortality. Fifth, because only Korean incident dialysis patients were
included, the association between AIP and mortality may not be generalized to other ethnic
groups or races. Lastly, we did not fully investigate the association between the AIP and cardio-
vascular mortality via sensitivity analyses due to the small number of cardiovascular deaths. A
future study is needed to clarify this issue. Notwithstanding these limitations, our study was
the first investigation to determine the independent prognostic value of the AIP in a nation-
wide prospective dialysis cohort.
Conclusions
The current study demonstrated that both the highest and the lowest AIP groups were signifi-
cantly associated with increased risk of all-cause mortality, showing a U-shaped association in
incident dialysis patients. Furthermore, a U-shaped association between the AIP and all-cause
mortality was significant in non-diabetic and underweight to normal BMI patients. These
findings suggest that further studies are needed to identify targets and subgroups that can ben-
efit from interventions of the AIP in ESRD patients.
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